Detailed introduction to the interactions between Vanzacato/Tizacaftor/Deuterated Ivacaftor composite tablets and other drugs

Vanzacaftor/tezacaftor/deuterivacaftor composite tablet (vanzacaftor, tezacaftor and deutivacaftor), as a new triple combinationCFTR modulator, may have complex interactions with other drugs in the treatment of cystic fibrosis. These interactions require clinicians and patients to pay great attention. This drug is mainly metabolized by the CYP3A enzyme system. This characteristic determines that it will have significant effects when combined with drugs that affect CYP3A activity. When used concurrently with drugs that are strong or moderately potent CYP3A inducers such as carbamazepine, phenytoin, rifampicin, there will be a significant decrease in vanzacato< span>/The systemic exposure of tizacaftor/Deuterated ivacaftor composite tablets may lead to a significant reduction in the therapeutic effect. Therefore, the combined use of such drugs should be avoided in clinical practice. If combined use is indeed necessary, the efficacy needs to be closely monitored and dosage adjustments should be considered.

On the other hand, interactions withCYP3Ainhibitors are also worthy of caution. When vanzacato/tizacaftor/deuterated ivacaftor compound tablets is used with strong CYP3A inhibitors such as ketoconazole, itraconazole, or moderate inhibitors such as red When drugs such as amoxicillin and ciprofloxacin are used together, the blood concentration of the active ingredient of vanzacato/tizakato/Deuterated Ivacaftor Complex Tablets will be significantly increased, thereby increasing the risk of adverse reactions. In this case, the doctor may need to consider temporarily reducing the dose of vanzacato/tizacaftor/deuterated ivacaftor combination tablets or choosing an alternative drug. It is important to note that this drug interaction may last for a long time, so after stopping the CYP3A inhibitor, continuous monitoring is required for a period of time to ensure that the drug concentration returns to a safe and effective level.

In addition to metabolism-related interactions, vanzacaftor/tizacaftor/Deuterated ivacaftor compound tablets itself may exacerbate existing liver damage. Clinical observations show that patients receiving treatment may experience elevated transaminases, and in severe cases, drug-induced liver injury and liver failure may occur. Therefore, for patients who are taking other hepatotoxic drugs, such as certain anti-tuberculosis drugs, anti-epileptic drugs, etc., combined useVanzacato/Tizacaftor/Deuterated ivacaftor composite tablets require extra caution. All patients must undergo a comprehensive liver function assessment before starting treatment and have liver function indicators monitored regularly during treatment. For patients with existing liver dysfunction, especially patients with severe hepatic impairment of Child-Pugh C grade, the use of this drug should be avoided; patients with moderate hepatic impairment of Child-Pugh B grade also need to fully evaluate the risk-benefit ratio before deciding whether to use it.

Anaphylaxis is also a drug interaction risk that requires special attention. Postmarketing surveillance data shows that severe hypersensitivity reactions, including life-threatening conditions such as anaphylactic shock, have been reported with drugs containing similar ingredients. Therefore, if you have a history of allergies to ingredients such as elexacaftor, tezacaftor or ivacaftor For patients with vanzacato/tizakato/deuterated ivacaftor composite tablets the risks must be fully assessed before use. If allergic symptoms such as rash, urticaria, difficulty breathing, etc. occur during treatment, the drug should be discontinued immediately and appropriate medical measures should be taken. In addition, children and adolescent patients under the age of 18 also need to pay attention to the risk of cataracts. It is recommended to undergo regular eye examinations before and during use, especially when other drugs that may affect lens metabolism are used together. They need to be more vigilant.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf